Pharma IQ | 10/13/2010
Mandar Kodgule, Head of Intellectual Property and Strategic Planning at Wockhardt, answers this question as well as offering the top five strategic considerations to sustain a healthy polymorph patent portfolio and to create polymorphic wealth. In this interview with Helen Winsor from Pharma IQ, he also touches upon how the regulatory landscape is changing and what impact it is having on enforceability of polymorph patents. Kodgule also addresses the issue of excessive innovation...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
SmartLab Exchange Europe
February 25 - 26, 2025
Novotel Amsterdam City, Netherlands
Register Now |
View Agenda |
Learn More
SmartLab Exchange USA 2025
08 - 09 April, 2025
Le Méridien, Fort Lauderdale, Florida, USA
Register Now |
View Agenda |
Learn More